BRAF and melanoma: In accordance, a very recent prospective study to evaluate exosomal-PD-L1 expression from 100 melanoma patients treated with immune checkpoint inhibitors and BRAF/MEK inhibitors, showed that tumor EXOs carrying PD-L1 had immunosuppressive properties since they were as efficient as the melanoma cell at inhibiting T-cell activation.